Suppr超能文献

罕见表皮生长因子受体(EGFR)突变型肺腺癌患者的逆转录聚合酶链反应(RT-PCR)误诊:二代测序(NGS)是唯一的解决办法吗?

RT-PCR Misdiagnosis of Patient with Rare EGFR Mutation Lung Adenocarcinoma: Is NGS the Only Solution?

作者信息

Piekarczyk Piotr, Lechowicz Urszula, Szopiński Janusz, Polaczek Mateusz, Błasińska Katarzyna, Modrzewska Katarzyna

机构信息

3rd Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.

Department of Genetics and Clinical Immunology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.

出版信息

Diagnostics (Basel). 2025 Mar 25;15(7):842. doi: 10.3390/diagnostics15070842.

Abstract

Molecular testing plays a crucial role in lung cancer diagnosis and management. While single-gene tests (SGTs) remain an important diagnostic tool, developments in novel methods such as next generation sequencing (NGS) provide a more precise mutational profile and enable the targeted treatment of a larger scope of mutation-driven cancers. We present a case of a patient with a rare variant lung adenocarcinoma, who was misdiagnosed using a SGT. The initial treatment with immunotherapy was unsuccessful. The patient could have benefited if NGS had been performed instead of traditional real-time polymerase chain reaction (RT-PCR) and if adequate tyrosine kinase inhibitor treatment was initiated at the time of diagnosis.

摘要

分子检测在肺癌的诊断和管理中起着至关重要的作用。虽然单基因检测(SGTs)仍然是一种重要的诊断工具,但新一代测序(NGS)等新方法的发展提供了更精确的突变图谱,并能够对更大范围的由突变驱动的癌症进行靶向治疗。我们报告了一例罕见的变异型肺腺癌患者,该患者使用单基因检测被误诊。最初的免疫治疗未成功。如果当时进行的是NGS而非传统的实时聚合酶链反应(RT-PCR),并且在诊断时就开始进行充分的酪氨酸激酶抑制剂治疗,该患者可能会受益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89c2/11988652/f20034b557c8/diagnostics-15-00842-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验